Eligo Bioscience
Eligo Bioscience is a Paris-based clinical-stage biotech developing the Eligobiotics platform for in vivo CRISPR-based gene editing of the microbiome, targeting inflammatory skin disorders, infectious diseases, and cardiac inflammation in patients via pharma partnerships.
- Company typePrivate
- Founded2015
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Eligo Bioscience does
Eligo Bioscience is a privately held, clinical-stage biotechnology company headquartered in Paris, France, developing a proprietary platform for in vivo gene editing of the microbiome. Founded in 2015 by CRISPR pioneers from The Rockefeller University and MIT, the company's Eligobiotics platform uses engineered phage-derived particles to deliver DNA payloads — including CRISPR-Cas nucleases, base editors, and therapeutic genes — directly into bacterial populations in the body, enabling precise, strain-specific modification or elimination of targeted bacteria without affecting beneficial commensals.
The platform comprises three core modalities: SSAM (Sequence-Specific Anti-Microbials) for CRISPR-based killing of harmful bacteria, GEM (Genome Editing of the Microbiome) for base editing of bacterial DNA without killing the cells, and FAME (Function Addition to the Microbiome) for programming commensal bacteria to express therapeutic proteins. Its lead programs are EB003, an oral candidate for Shiga-toxin producing E. coli infection leading to Hemolytic Uremic Syndrome (FDA Orphan Drug, Rare Pediatric Disease, and EMA Orphan Designations), and EB005, a topical candidate for moderate-to-severe acne vulgaris developed in partnership with GSK in a deal worth up to $224 million.
Eligo has no commercialized products and operates a pre-revenue business model that combines pharmaceutical licensing and co-development partnerships (e.g., GSK), non-dilutive grants from the French government (France 2030), the European Commission, and CARB-X, and venture financing from Khosla Ventures, Sanofi Ventures, Bpifrance, and Seventure Partners. The company controls 25+ patent families covering 100+ bacterial species, including the earliest patent priority (2013) in CRISPR microbiome editing, and won a US patent interference that canceled five competing SNIPR Biome patents. As of the latest available data, Eligo employs approximately 35 people and is advancing EB005 toward a Phase 1b/2a clinical trial in acne.
Eligo Bioscience firmographics
Firmographics- Name
- Eligo Bioscience
- Legal name
- Eligo Bioscience SA
- Website
- https://eligo.bio
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Eligo Bioscience is a Paris-based clinical-stage biotech developing the Eligobiotics platform for in vivo CRISPR-based gene editing of the microbiome, targeting inflammatory skin disorders, infectious diseases, and cardiac inflammation in patients via pharma partnerships.
- Ownership category
- akta.pro rank
Eligo Bioscience industry classification
Industry- Product category
- Microbiome Genetic Medicines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)
Keywords
Where Eligo Bioscience is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Eligo Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Licensing and Partnership Deals: Eligo generates revenue through strategic licensing agreements and research collaborations with pharmaceutical companies. Examples include the GSK deal (up to $224M in license fees and milestone payments) and ongoing pharma partnerships.
- Non-dilutive Funding: Government grants and non-dilutive funding from organizations including French government (France 2030), European Commission, CARB-X, and Bpifrance to support R&D activities.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Eligo Bioscience product offering
Product offeringCore offering
Eligo Bioscience develops the Eligobiotics platform, a first-in-class proprietary modality that uses engineered phage-derived particles to deliver DNA payloads (CRISPR-Cas nucleases, base editors, or therapeutic genes) into bacterial populations of the microbiome for in vivo gene editing. The company applies this platform to develop therapeutic drug candidates targeting diseases driven by bacterial genes, including EB003 for STEC infection/Hemolytic Uremic Syndrome and EB005 for moderate to severe acne vulgaris (in partnership with GSK).
Product overview
Eligo Bioscience has developed the GEM (Gene Editing of the Microbiome) platform, a first-in-class proprietary technology for in vivo gene editing of the microbiome. The platform encompasses three core modalities delivered through Eligobiotics®: SSAM (Sequence-Specific Anti-Microbials) for CRISPR-based bacterial killing, GEM for base editing, and FAME for therapeutic gene addition. The company's pipeline includes EB003 (lead candidate for STEC/HUS), EB005 (acne program with GSK), and programs targeting inflammatory cardiac diseases. Eligo is advancing toward clinical trials with the world's first topical CRISPR treatment for moderate to severe acne.
Differentiator
Problem solved
Functional benefit
Products and services
- Eligobiotics Platform A first-in-class proprietary modality using phage-derived particles to deliver DNA payloads encoding CRISPR systems into bacterial populations of the microbiome, enabling precise gene editing, killing, or functionalization of target bacteria in vivo. Licensed and co-developed with pharmaceutical partners for therapeutic applications.
- EB003 Lead drug candidate using SSAM technology for treatment of Shiga-toxin producing E. coli (STEC) infection leading to Hemolytic Uremic Syndrome (HUS). Granted FDA Orphan Drug Designation and Rare Pediatric Disease designation; also received EMA Orphan Drug Designation.
- EB005 Discovery program targeting moderate to severe acne vulgaris using Eligobiotics technology to precisely modify skin microbiome composition. Developed in partnership with GSK in a deal worth up to $224 million.
Quantifiable outcome
- Up to 99.7% editing efficiency achieved in animal gut microbiome models
- +3 more outcomes
Companies that use Eligo Bioscience
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles1 record
Eligo Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Eligo Bioscience partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and core.
- Biose IndustriesmajorPartnership with globally recognized CDMO specializing in microbial fermentation for GMP bioproduction scaling. Supports acceleration of clinical-grade manufacturing for Eligo's topical gene delivery vector.
- Kantonsspital St. GallenmajorStrategic alliance to develop gene editing therapy for inflammatory cardiac diseases induced by bacterial mimicry. Combines Ludewig group's research on bacterial peptide mimics with Eligo's in vivo gene editing platform. Eligo gains access to patient samples, data, and animal models.
- GSK (GlaxoSmithKline)coreResearch and option agreement for advancement of Eligobiotics (EB005) for treatment of acne vulgaris using CRISPR-based therapeutic for strain-specific microbiome modulation. Eligo eligible to receive up to $224M in license fees and milestone payments plus royalties on global sales.
- Institut PasteurcoreAcademic collaboration hub; Eligo cofounders Prof. David Bikard (Synthetic Biology Lab Head) and Prof. Luciano Marraffini are from Rockefeller. Co-founder Tim Lu from MIT. Provides ongoing research collaboration and scientific expertise.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Eligo Bioscience competitors and assessment
Company assessmentDirect peers
- Vedanta Biosciences: Develops defined bacterial consortia as live biotherapeutic products for immune-mediated diseases. Operates in the same microbiome therapeutics space with similar pharma partnership and licensing economics (e.g., Bristol Myers Squibb collaboration).
- Novome Biotechnologies: Engineered microbiome therapeutics company developing genetically modified bacteria for diseases including hyperoxaluria. Closely comparable in approach (genetic engineering of commensal bacteria) with similar platform-level licensing potential.
- Assembly Biosciences: Clinical-stage biotech developing microbiome-targeted therapies including engineered B. infantis and small-molecule approaches to microbiome modulation. Comparable indication set (gastrointestinal, immunology) and partner-driven commercialization model.
- Seres Therapeutics: Clinical-stage microbiome therapeutics company developing defined bacterial consortia to treat disease. Targets similar indications including inflammatory and infectious diseases and serves as a benchmark for microbiome therapeutic development pathways and commercialization.
- SNIPR Biome: Direct competitor in CRISPR-based microbiome engineering. SNIPR Biome develops phage-delivered CRISPR antimicrobials to selectively kill bacteria, the same core modality as Eligo's SSAM platform. Eligo won a US patent interference against SNIPR Biome in 2021.
- Finch Therapeutics: Microbiome therapeutics company developing Full-Spectrum Microbiota products for inflammatory and infectious diseases. Directly comparable clinical-stage peer pursuing microbiome-based therapies through pharma partnerships.
Emerging players
- Beam Therapeutics: Clinical-stage base editing company developing precision genetic medicines. Comparable in base editing technology overlap with Eligo's GEM platform, though Beam targets human genome editing versus bacterial genome editing.
- Second Genome: Microbiome-focused drug discovery and development company identifying bacterial targets and small-molecule modulators. Comparable in microbiome therapeutic focus but uses small molecules rather than gene editing as the modality.
- Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company co-founded by Eligo scientific cofounder Luciano Marraffini. Indirectly comparable through shared CRISPR therapeutic foundation; Intellia targets human gene editing while Eligo targets bacterial gene editing.
Broad incumbents
- Rebiotix (Ferring Pharmaceuticals): Ferring's microbiome division developing Microbiota Restoration Therapy for recurrent C. difficile infection. Acquired by Ferring, provides an example of a microbiome therapeutic reaching late-stage development and commercialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Eligo Bioscience social profiles
Digital presenceEligo Bioscience compliance and trust
Trust signalCompliance3 records
Eligo Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eligo Bioscience leadership team
Management profileNumber of profiles
Profiles14 records
Eligo Bioscience funding detail
Funding detailFunding overview
Funding rounds10 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eligo Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eligo Bioscience
What does Eligo Bioscience do?
Eligo Bioscience develops the Eligobiotics platform, a first-in-class proprietary modality that uses engineered phage-derived particles to deliver DNA payloads (CRISPR-Cas nucleases, base editors, or therapeutic genes) into bacterial populations of the microbiome for in vivo gene editing. The company applies this platform to develop therapeutic drug candidates targeting diseases driven by bacterial genes, including EB003 for STEC infection/Hemolytic Uremic Syndrome and EB005 for moderate to severe acne vulgaris (in partnership with GSK).
Is Eligo Bioscience a public or private company?
Eligo Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was Eligo Bioscience founded?
Eligo Bioscience was founded in 2015. It employs 11 to 50 people.
Where is Eligo Bioscience based?
Eligo Bioscience is headquartered in Paris, France, in the Europe region.
How does Eligo Bioscience make money?
Two revenue lines are on record. Pharmaceutical Licensing and Partnership Deals are the primary driver. The others are non-dilutive Funding.
Who are Eligo Bioscience's main competitors?
Direct peers on record are Vedanta Biosciences, Novome Biotechnologies, Assembly Biosciences, Seres Therapeutics, SNIPR Biome and Finch Therapeutics. Emerging players are Beam Therapeutics, Second Genome and Intellia Therapeutics. Rebiotix (Ferring Pharmaceuticals) is listed as a broad incumbent.
Does Eligo Bioscience have an API?
No public API is recorded for Eligo Bioscience.
What industry is Eligo Bioscience in?
Eligo Bioscience's product category is Microbiome Genetic Medicines. Its primary akta.pro industry code is HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.